BioWorld

Aug. 28, 2003

View Archived Issues

AM1241, A Synthetic Compound, Activates Cannabinoid Painkiller, Proven In Rat, Mice Experiments

Read More

IPO Trend Hasn't Fizzled As TolerRx Plans $75M Offering

Read More

BioCryst Quits 3-Dimensional Deal To Spend Funds Elsewhere

Read More

Nymox Raises $12M Privately To Provide Three Years' Cash

Read More

Other News To Note

Read More

Flamel Finds New Basulin Partner, Signs $165M Bristol-Myers Deal

Flamel Technologies SA again has partnered its recombinant human insulin product, Basulin; this time, signing a deal with Bristol-Myers Squibb Co. valued at up to $165 million. (BioWorld Today) Read More

Metabolex Privately Raises $27M For MBX-102 Phase II Program

Read More